Vaxcyte, Inc. - COMMON STOCK (PCVX) Institutional Ownership

13F Institutional Holders and Ownership History from Q2 2020 to Q4 2025

Type / Class
Equity / COMMON STOCK
Symbol
PCVX on Nasdaq
Shares outstanding
129,929,313
Price per share
$46.14
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
141,274,894
Total reported value
$5,088,535,411
% of total 13F portfolios
0.01%
Share change
-6,311,713
Value change
-$216,626,417
Number of holders
280
Price from insider filings
$46.14
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Vaxcyte, Inc. - COMMON STOCK (PCVX) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
FMR LLC 10% +7.8% $414,340,651 +$32,457,883 13,132,826 +8.5% FMR LLC 29 Aug 2025
JANUS HENDERSON GROUP PLC 10% -12% $472,013,392 -$57,168,819 13,104,203 -11% JANUS HENDERSON GROUP PLC 30 Sep 2025
RA CAPITAL MANAGEMENT, L.P. 9.9% $363,524,328 12,964,491 RA Capital Management, L.P. 31 Mar 2025
BlackRock, Inc. 7.6% $275,510,890 9,825,638 BlackRock, Inc. 31 Mar 2025
T. Rowe Price Investment Management, Inc. 6.4% $299,523,446 8,315,476 T. Rowe Price Investment Management, Inc. 30 Sep 2025

As of 30 Sep 2025, 280 institutional investors reported holding 141,274,894 shares of Vaxcyte, Inc. - COMMON STOCK (PCVX). This represents 109% of the company’s total 129,929,313 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Vaxcyte, Inc. - COMMON STOCK (PCVX) together control 87% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
JANUS HENDERSON GROUP PLC 10% 13,104,203 -11% 0.22% $472,046,873
FMR LLC 9.6% 12,509,933 +3% 0.02% $450,607,771
VANGUARD GROUP INC 9.5% 12,320,453 +2.7% 0.01% $443,782,718
RA CAPITAL MANAGEMENT, L.P. 9.2% 11,965,991 0% 5.3% $431,014,996
BlackRock, Inc. 7.7% 9,955,978 -6.4% 0.01% $358,614,332
T. Rowe Price Investment Management, Inc. 6.4% 8,315,295 +39% 0.18% $299,517,000
WELLINGTON MANAGEMENT GROUP LLP 3.9% 5,032,771 +1.6% 0.03% $181,280,411
STATE STREET CORP 3.7% 4,785,889 -3.2% 0.01% $172,387,722
D. E. Shaw & Co., Inc. 3.3% 4,290,790 +39% 0.12% $154,554,256
Paradigm Biocapital Advisors LP 2.9% 3,784,755 +12% 4% $136,326,875
WESTFIELD CAPITAL MANAGEMENT CO LP 2.9% 3,732,715 +22% 0.56% $134,452,394
Kynam Capital Management, LP 2.4% 3,071,588 0% 8.2% $110,638,600
Deep Track Capital, LP 2.3% 3,000,000 +40% 3% $108,060,000
GEODE CAPITAL MANAGEMENT, LLC 2.2% 2,884,040 -4.2% 0.01% $103,898,128
PRICE T ROWE ASSOCIATES INC /MD/ 1.3% 1,688,483 -47% 0.01% $60,820,000
JPMORGAN CHASE & CO 1.2% 1,565,036 +31% 0% $56,372,597
Eversept Partners, LP 1.1% 1,421,983 +9.5% 3.9% $51,219,828
Pivotal bioVenture Partners Investment Advisor LLC 1.1% 1,372,425 +5.2% 29% $49,434,749
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 1% 1,293,407 -8.8% 0.01% $46,588,520
MAVERICK CAPITAL LTD 0.99% 1,289,567 -1.6% 0.62% $46,450,203
JENNISON ASSOCIATES LLC 0.9% 1,170,899 -16% 0.02% $42,175,782
NORTHERN TRUST CORP 0.83% 1,073,346 -4.3% 0% $38,661,924
Pictet Asset Management Holding SA 0.79% 1,029,629 -12% 0.04% $37,087,237
GOLDMAN SACHS GROUP INC 0.75% 975,377 +4.4% 0.01% $35,133,079
ROYAL BANK OF CANADA 0.73% 949,049 +27% 0.01% $34,184,000

Institutional Holders of Vaxcyte, Inc. - COMMON STOCK (PCVX) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 576,607 $26,605,054 +$14,692,376 $46.14 8
2025 Q3 141,274,894 $5,088,535,411 -$216,626,417 $36.02 280
2025 Q2 147,479,114 $4,794,596,759 -$48,096,965 $32.51 292
2025 Q1 133,025,162 $5,021,088,292 -$42,914,635 $37.76 301
2024 Q4 140,783,830 $11,525,462,780 +$274,442,424 $81.86 318
2024 Q3 135,391,915 $15,464,691,636 +$1,408,782,383 $114.27 325
2024 Q2 122,574,057 $9,263,699,325 +$346,603,952 $75.51 266
2024 Q1 117,896,146 $8,050,515,702 +$1,055,610,820 $68.31 235
2023 Q4 303,644 $19,085,979 +$1,632,634 $62.80 3
2023 Q3 100,553,929 $5,124,369,588 +$57,935,535 $50.98 198
2023 Q2 99,204,016 $4,954,006,523 +$833,008,120 $49.94 194
2023 Q1 84,085,732 $3,151,509,133 +$160,592,889 $37.48 183
2022 Q4 81,518,873 $3,908,768,132 +$1,140,794,616 $47.95 191
2022 Q3 56,239,870 $1,350,089,448 +$123,779,992 $24.00 117
2022 Q2 51,280,790 $1,115,849,315 +$30,484,247 $21.76 102
2022 Q1 49,826,353 $1,203,215,127 +$124,911,152 $24.15 83
2021 Q4 44,686,066 $1,062,727,175 +$31,489,295 $23.79 81
2021 Q3 43,049,092 $1,092,175,829 -$1,297,500 $25.37 75
2021 Q2 43,207,993 $972,418,431 -$13,497,983 $22.51 72
2021 Q1 36,308,797 $716,870,214 +$25,393,622 $19.75 71
2020 Q4 42,210,896 $1,117,586,991 +$56,603,061 $26.57 81
2020 Q3 37,761,937 $1,857,382,730 +$103,777,788 $49.38 60
2020 Q2 35,950,832 $1,126,753,000 +$1,126,753,402 $31.61 38